Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer

The National Cancer Institute,Laboratory of Molecular Biologyseeks parties interested in collaborative research to further co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers. The antibody was able to inhibit tumor growth in mouse xenograft models, and corresponding immunotoxins were able to inhibit tumor cell growth in vitroMesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. This selective expression makes mesothelin an excellent candidate for targeted therapeutics such as monoclonal antibodies (mAbs) and corresponding chimeric molecules. Unfortunately, current anti-mesothelin mAb candidates have drawbacks, such as competition with a serum protein (MUC16/CA125) for binding to mesothelin, the formation of neutralizing antibodies because they are non-human antibodies, and the inability to trigger complement-dependent cytotoxicity (CDC).    In order to address this concern, NIH inventors generated two single domain human mAbs: SD1 and SD2.   SD1 recognizes a unique epitope in region III of mesothelin which is not out-competed for binding by MUC16/CA125.  SD1 was also capable of triggering CDC, as well as antibody-dependent cellular cytotoxicity (ADCC). Due to its human origin, SD1 is also less likely to elicit the formation of neutr alizing antibodies when a...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research